Navigation Links
Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients
Date:11/1/2008

dose has occurred in patients on PEGINTRON therapy. Aggressive behavior sometimes directed towards others has occurred in patients with and without a previous psychiatric disorder during PEGINTRON and/or INTRON A treatment and follow-up. If patients develop psychiatric problems, including clinical depression, it is recommended that patients be carefully monitored during treatment and in the 6-month follow-up period. If psychiatric symptoms persist or worsen, or suicidal ideation or aggressive behavior towards others is identified, it is recommended that treatment with PEGINTRON and/or INTRON A be discontinued, and the patient be carefully followed with psychiatric intervention, as appropriate. Cases of encephalopathy have been observed in some patients, usually elderly, treated with higher doses of PEGINTRON and/or INTRON A. Ischemic and hemorrhagic cerebrovascular events have been observed in patients treated with interferon alpha therapies, including PEGINTRON and INTRON A. Dental and periodontal disorders have been reported in patients receiving PEGINTRON or INTRON A in combination with REBETOL therapy.

Please see important full U.S. prescribing information and the Medication Guide for PEGINTRON at http://www.schering-plough.com.

About Schering-Plough

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response
2. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
3. Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
4. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
5. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
6. Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
9. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
10. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... FRANKLIN, Ohio , Jan. 15, 2014  A novel wearable ... it easy and painless for patients to self-inject prescription drugs ... of disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic ... expected to grow to $220B by 2018, according to analysts.   ...
(Date:1/14/2014)... 2014  Luminex Corporation (Nasdaq: LMNX ) today announced ... of 2013 on Monday, February 3, 2014. A press release ... of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... operating highlights and financial results for the fourth quarter and ...
(Date:1/14/2014)... , Jan. 14, 2014 The Brandeis Medical Center, led ... a premier and affordable laser tattoo removal experience with ... Brandeis, focus is in providing high quality cosmetic services with cutting ... " Southern California has seen a ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... Fla., July 5, 2011 MSC Care Management, a ... management solutions to the workers, compensation industry, has launched ... to help relieve the administrative burden for claims adjusters ... a proprietary online tool that allows for faster and ...
... Tourette Syndrome Association, Inc., (TSA) has unveiled a 115-square ... generate awareness and acceptance of all people living with ... "We Have Tourette,s But Tourette,s Doesn,t Have Us" is ... everyday with the symptoms of involuntary sounds and movements ...
Cached Medicine Technology:MSC CareConnect Provides Real-Time, Online Communication and Referral Management to Claims Professionals 2EHE International Showcases The National Tourette Syndrome Association, Inc. with Month-Long Window Display in Rockefeller Center Plaza 2
(Date:4/23/2014)... predict which patients might suffer potentially fatal side-effects from ... assesses brain scans using pattern recognition software similar to ... been developed by researchers at Imperial College London. Results ... which used the software are published in the journal ... 15 million people each year worldwide. Ischemic strokes are ...
(Date:4/23/2014)... benefits of probiotics, antioxidants and other nutritional compounds, more ... industry is getting in on the action. But legitimate ... the industry is responding with clinical research to shore ... Chemical & Engineering News (C&EN), the weekly ... M. Bomgardner, a senior editor at C&EN, writes that ...
(Date:4/23/2014)... SEATTLE, Washington, April 21, 2014 Five for-profit ... total of $1.25 million in Proof of Concept ... from ideas into commercial products, the Life Sciences ... a $300,000 Entrepreneur Mentoring Program grant to the ... a statewide advisory network to train the next ...
(Date:4/23/2014)... Effects of Midlife Occupational and Leisure Time Physical Activity ... physical activity in midlife increases the risk of mobility ... the risk. This is found in a study which ... The study was conducted at the Gerontology Research Center ... , Heavy physical labor is often repetitive, wears the ...
(Date:4/23/2014)... shown that proliferation of endogenous neural precursor cells ... and axons. From the perspective of neural plasticity, ... University in China observed the effects of functional ... proliferation and expression of basic fibroblast growth factor ... on the infarct side. The researchers found that ...
Breaking Medicine News(10 mins):Health News:Airport security-style technology could help doctors decide on stroke treatment 2Health News:Airport security-style technology could help doctors decide on stroke treatment 3Health News:LSDF announces commercialization grants and Entrepreneur Mentoring Program 2Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2
... of bird flu which had reached a feverish pitch early in ... //if the virus has actually beaten a retreat. , ... flu is dynamic in the winter months, as the virus can ... The H5N1 virus which had earlier restricted itself to Southeast Asia ...
... the University of North Carolina at Chapel Hill School of ... according to a study by an international group of researchers. ... by Dr. Carol Otey and her former student, Dr. Mana ... in Boston. Otey has shown that palladin is involved in ...
... basic symptoms associated with ovarian cancer may aid clinicians ... a new study.// This index is expected to serve ... details of this study is published in the January ... of the American Cancer Society, the study reveals that ...
... thousands of quails at a farm in Kimje.// It was ... a farm in Kimje, 262 kilometers southwest of Seoul to the ... in the farm of the latest outbreak. ,This recent ... starting with an first outbreak of highly virulent H5N1 virus on ...
... (Australia) government has decided //to toughen its laws on anti-smoking. ... carrying children. This comes in the wake of ... dies every 18 days, when exposed to cigarette smoke. ... Queenslanders Report, 2006, made these comments. ,A review ...
... University School of Medicine have found out that successful lung ... in many smokers. This study published in the December issue ... look at smoking relapse among people who were "forced" to ... found that close to half of 154 smokers who had ...
Cached Medicine News:Health News:Gene Discovered by Researchers Tied to Pancreatic Cancer 2Health News:A Basic Symptom Index For Early Detection Of Ovarian Cancer 2Health News:Lung Cancer Surgeries Doesn’t Help Breaking Nicotine Dependence in Smoker 2Health News:Lung Cancer Surgeries Doesn’t Help Breaking Nicotine Dependence in Smoker 3
... components that comprise the SmartPill GI ... comprise the SmartPill GI Monitoring System: ... Receiver software and SmartPill MotiliGI software. ... indispensable parts of the SmartPill GI ...
... for POLYGRAM NET™ (PNET) works with ... record and analyze pressure, swallow, and ... procedures. The PNET software and Polygraf ... water-perfused manometry catheters and the RespSponse™ ...
... Advanced pH Analysis for POLYGRAM NET™ ... Testing Application. Like the standard application, Advanced ... by either the Digitrapper™ Catheter-Based pH Recorder ... ,Designed primarily for use by clinical ...
Capillaries available in glass and "non-PVC" plastic. Match different analyzer requirements. Variety of sizes match sample-volume requirements of individual analyzers....
Medicine Products: